Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Most patients (21 of 26; 80.8%) had TRAEs of Grade 2 or lower, consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Grade 3 ...
Recursion Pharmaceuticals (NASDAQ: RXRX) priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share, according to a press release issued Oct. 15, ...
Recursion reported two confirmed responses in endometrial cancer and a 91.7% disease-control rate at doses of 45 mg or higher; Sanofi optioned a candidate.
Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...
Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...
Two researchers building a startup around recursive self-improvement argue the term has been diluted to near-meaninglessness. Dhaval Adjodah, ...
Artificial intelligence (AI) has made groundbreaking strides in recent years, yet achieving true self-evolution—an AI ...
AI makes itself better.When I see the term "recursive self-improvement," I imagine a future where AI gets smarter and smarter ...
A fact I recently learnedI recently finished reading a book on automata, and according to that book, Turing machines, lambda calculus, and recursive functions all have the same computational ...
13d
Experts Reveal What Could Actually Happen If AI Enters ‘Recursive Self-Improvement’ — And It's Scary
Right now, leading artificial intelligence models need human supervision to improve—but a popular theory known as "recursive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results